Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:N-Ribosylhistidine)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteAnalysis Type
ST004153 AN006895 Multi-omics Study of Small Intestine Adaptation After Total Colectomy in a Rat model Feces Rat Shanghai Jiao Tong University LC-MS
ST003144 AN005159 On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity Blood Plasmodium falciparum Malaria Monash University LC-MS
ST003053 AN005006 Providing insight into the mechanism of action of Cationic Lipidated Oligomers (CLOs) using metabolomics Bacterial cells Staphylococcus aureus Bacterial infection Monash University LC-MS
ST003036 AN004977 Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 2 Bacterial cells Pseudomonas aeruginosa Bacterial infection Monash Institute of Pharmaceutical Sciences LC-MS
ST002792 AN004542 Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002775 AN004517 Zebrafish Retina Regeneration Metabolomics - 3 Days Post Crush Eye tissue Zebrafish Eye disease University of Miami LC-MS
ST002761 AN004487 Metabolic responses of normal rat kidneys to a high salt intake (Urine) Urine Rat Medical College of Wisconsin LC-MS
ST002760 AN004483 Metabolic responses of normal rat kidneys to a high salt intake (Kidney outer medulla) Kidney Rat Medical College of Wisconsin LC-MS
ST002760 AN004485 Metabolic responses of normal rat kidneys to a high salt intake (Kidney outer medulla) Kidney Rat Medical College of Wisconsin LC-MS
ST002108 AN003448 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3) Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002016 AN003284 Metabolomics of COVID patients Blood Human COVID-19 University of Virginia LC-MS
ST001205 AN002006 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Human Malaria Monash University LC-MS
ST001205 AN002006 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST001202 AN002000 Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites Cultured cells Human Malaria Monash University LC-MS
ST001202 AN002000 Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST001201 AN001998 Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Human Malaria Monash University LC-MS
ST001201 AN001998 Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST000546 AN000832 Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant Plasmodium Cells Plasmodium falciparum Malaria Monash University LC-MS
  logo